Biologics CDMO Market Growth, Demand & Opportunities

1. Biologics CDMO Market To Reach $31,839.7 Million by 2030 1 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

2. Due to the increasing elderly population, growing demand for medicines, rising investment in healthcare, and the constant introduction of new products, the global biologics CDMO market was valued at $13,173.7 million in 2021. This is expected to reach $31,839.7 million by 2030, at a CAGR of 10.3% from 2021 to 2030. With the rise in the cases of infections among people, pharma companies are engaging in partnerships with CDMOs for meeting the demand for antibiotics. A share of 50% in the biologics CDMO market was held by drug substances in 2021, and this trend is expected to continue in the years to come. This will be because of the rising number of biologics approvals, predominantly by the FDA, along with the strong clinical pipelines and dipping rates of biologic drug development failures. The highest subcontracting revenue from drug substance production attributes to the monoclonal antibody (mAb). Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/biologics-cdmo- market/report-sample Key Findings of Biologics CDMO Market Report • Mammalian cell culture is likely to contribute revenue of $17,983.2 million in 2030, progressing with a CAGR of over 10% in the coming years, due to the growing production of bi- and tri-specific antibodies and antibody–drug conjugates. • During COVID-19, the increasing requirement for vaccines and therapeutic antibodies has had a positive effect on the biologics CDMO market. Additionally, the pandemic exposed the flaws in the supply chain and the world’s dependence on developing markets for APIs and generics. • The demand for clinical services is on the rise because of the outsourcing by the biopharmaceutical industry. To lessen the risks associated with this phase of drug development, biologics CDMOs’ low drug costs and extensive experience are being leveraged by biopharma firms. • APAC is the largest and fastest-growing region in the market, with a CAGR of 10% during 2021−2030. This is attributable to an immense and quickly growing population demanding better access to medical drugs. • Furthermore, a surge in the GDP, government healthcare programs, and an increase in the rate of urbanization have extended the access to medical professionals and pharmacies for a large number of people. • As per the EFPIA, the pharmaceutical industry invested $46,144 million in 2020 in Europe for research, development, and introduction of new medicines. 2 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

3. India is a good prospect for the CDMO market as it has the FDA approval for a large number of medicines and is home to a highly competent workforce. With the improvement of healthcare ecosystem in emerging economies and growth of generic drug manufacturers, there will be a mammoth surge in the business of local CDMOs, as India has the potential to handle a vast number of products more lucratively. The research offers market size of the Biologics CDMO market for the period 2017–2030. Market Segmentation by Product Type Drug Product Drug Substance Market Segmentation by Cell Line Type Microbial Mammalian Viral Vector & Other Modalities Market Segmentation by Service Type Clinical Commercial Market Segmentation by Region North America Biologics CDMO Market • • • • • • • • oBy product type oBy cell line type oBy service type oBy country – U.S. and Canada Europe Biologics CDMO Market • oBy product type oBy cell line type oBy service type oBy country – Germany, France, U.K., Italy, Spain, and Rest of Europe Asia-Pacific (APAC) Biologics CDMO Market • oBy product type oBy cell line type oBy service type oBy country – China, India, Japan, Australia, South Korea, and Rest of APAC Latin America (LATAM) Biologics CDMO Market • oBy product type oBy cell line type 3 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

4. oBy service type oBy country – Brazil, Mexico, and Rest of LATAM Middle East and Africa (MEA) Biologics CDMO Market • oBy product type oBy cell line type oBy service type oBy country – Saudi Arabia, South Africa, and Rest of MEA 4 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

5. Disclaimer: P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies or organizations. P&S Intelligence is not responsible for any incorrect data provided by the key industry players of the concerned domain. The information or analysis in P&S Intelligence publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication, but cannot be guaranteed. P&S Intelligence does not endorse any product, service, or vendor depicted in its research publications. All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected by copyright. Under no circumstance can these be reproduced in any form without prior written agreement of their owners. An order for market research report is intended for internal use of the company only and not for disclosure to third parties or any other publication in general. No service, report, or part thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd. Kindly write to: enquiry@psmarketresearch.com B-13, Sector – 2, Noida, U.P. – 201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 5 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved